Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Operating Expenses (2021 - 2026)

bioAffinity Technologies has reported Operating Expenses over the past 5 years, most recently at $928636.0 for Q1 2026.

  • Quarterly Operating Expenses fell 32.11% to $928636.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Mar 2026, down 14.02% year-over-year, with the annual reading at $16.7 million for FY2025, 8.63% down from the prior year.
  • Operating Expenses was $928636.0 for Q1 2026 at bioAffinity Technologies, down from $4.7 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $5.2 million in Q4 2024 and troughed at $685279.0 in Q2 2022.
  • The 5-year median for Operating Expenses is $2.6 million (2023), against an average of $2.8 million.
  • Year-over-year, Operating Expenses skyrocketed 180.12% in 2023 and then tumbled 68.57% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $1.6 million in 2022, then skyrocketed by 180.12% to $4.6 million in 2023, then rose by 13.13% to $5.2 million in 2024, then decreased by 8.23% to $4.7 million in 2025, then tumbled by 80.37% to $928636.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Operating Expenses are $928636.0 (Q1 2026), $4.7 million (Q4 2025), and $3.7 million (Q3 2025).